A novel multi-functionalized multicellular nanodelivery system for non-small cell lung cancer photochemotherapy.
A549 Cells
Animals
Apoptosis
Biomimetics
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Cell Line, Tumor
Drug Carriers
/ chemistry
Erythrocyte Membrane
Erythrocytes
Humans
Liposomes
/ chemistry
Lung Neoplasms
/ drug therapy
Male
Mice
Mice, Inbred BALB C
Mice, Nude
Nanoparticle Drug Delivery System
Nanoparticles
/ chemistry
Neoplasms
Paclitaxel
/ pharmacology
Particle Size
Photochemotherapy
/ methods
RAW 264.7 Cells
Rats, Sprague-Dawley
Reactive Oxygen Species
Xenograft Model Antitumor Assays
Biomimetic
Liposomes
Nanoparticles
Photodynamic therapy
Red blood cell
Tumor
Journal
Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208
Informations de publication
Date de publication:
14 Aug 2021
14 Aug 2021
Historique:
received:
29
04
2021
accepted:
27
07
2021
entrez:
15
8
2021
pubmed:
16
8
2021
medline:
4
1
2022
Statut:
epublish
Résumé
A red blood cell membrane (RBCm)-derived drug delivery system allows prolonged circulation of an antitumor treatment and overcomes the issue of accelerated blood clearance induced by PEGylation. However, RBCm-derived drug delivery systems are limited by low drug-loading capacities and the lack of tumor-targeting ability. Thus, new designs of RBCm-based delivery systems are needed. Herein, we designed hyaluronic acid (HA)-hybridized RBCm (HA&RBCm)-coated lipid multichambered nanoparticles (HA&RBCm-LCNPs) to remedy the limitations of traditional RBCm drug delivery systems. The inner core co-assembled with phospholipid-regulated glycerol dioleate/water system in HA&RBCm-LCNPs met the required level of blood compatibility for intravenous administration. These newly designed nanocarriers had a honeycomb structure with abundant spaces that efficiently encapsulated paclitaxel and IR780 for photochemotherapy. The HA&RBCm coating allowed the nanocarriers to overcome the reticuloendothelial system barrier and enhanced the nanocarriers specificity to A549 cells with high levels of CD44. These properties enhanced the combinatorial antitumor effects of paclitaxel and IR780 associated with microtubule destruction and the mitochondrial apoptotic pathway. The multifunctional HA&RBCm-LCNPs we designed expanded the functionality of RBCm and resulted in a vehicle for safe and efficient antitumor treatment.
Sections du résumé
BACKGROUND
BACKGROUND
A red blood cell membrane (RBCm)-derived drug delivery system allows prolonged circulation of an antitumor treatment and overcomes the issue of accelerated blood clearance induced by PEGylation. However, RBCm-derived drug delivery systems are limited by low drug-loading capacities and the lack of tumor-targeting ability. Thus, new designs of RBCm-based delivery systems are needed.
RESULTS
RESULTS
Herein, we designed hyaluronic acid (HA)-hybridized RBCm (HA&RBCm)-coated lipid multichambered nanoparticles (HA&RBCm-LCNPs) to remedy the limitations of traditional RBCm drug delivery systems. The inner core co-assembled with phospholipid-regulated glycerol dioleate/water system in HA&RBCm-LCNPs met the required level of blood compatibility for intravenous administration. These newly designed nanocarriers had a honeycomb structure with abundant spaces that efficiently encapsulated paclitaxel and IR780 for photochemotherapy. The HA&RBCm coating allowed the nanocarriers to overcome the reticuloendothelial system barrier and enhanced the nanocarriers specificity to A549 cells with high levels of CD44. These properties enhanced the combinatorial antitumor effects of paclitaxel and IR780 associated with microtubule destruction and the mitochondrial apoptotic pathway.
CONCLUSIONS
CONCLUSIONS
The multifunctional HA&RBCm-LCNPs we designed expanded the functionality of RBCm and resulted in a vehicle for safe and efficient antitumor treatment.
Identifiants
pubmed: 34391438
doi: 10.1186/s12951-021-00977-3
pii: 10.1186/s12951-021-00977-3
pmc: PMC8364713
doi:
Substances chimiques
Drug Carriers
0
Lipid Nanoparticles
0
Liposomes
0
Nanoparticle Drug Delivery System
0
Reactive Oxygen Species
0
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
245Subventions
Organisme : National Natural Science Foundation of China
ID : 82074031
Organisme : National Natural Science Foundation of China
ID : 82074279
Informations de copyright
© 2021. The Author(s).
Références
Science. 2000 Jun 16;288(5473):2051-4
pubmed: 10856220
J Immunol. 1986 Mar 1;136(5):1772-6
pubmed: 2419413
Int J Nanomedicine. 2016 Sep 20;11:4799-4818
pubmed: 27703348
Nanoscale. 2017 Jul 27;9(29):10327-10334
pubmed: 28702661
Eur J Cancer. 2011 Dec;47(18):2750-61
pubmed: 21741231
Adv Healthc Mater. 2017 Feb;6(4):
pubmed: 27990775
Adv Drug Deliv Rev. 2018 Sep;134:122-137
pubmed: 30267743
Cell. 1995 Nov 3;83(3):493-501
pubmed: 8521479
J Nanobiotechnology. 2020 Sep 4;18(1):124
pubmed: 32887622
Adv Exp Med Biol. 2018;1064:45-59
pubmed: 30471025
Immunobiology. 2013 May;218(5):725-32
pubmed: 22995937
Oncol Lett. 2016 Aug;12(2):983-988
pubmed: 27446381
Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3336-40
pubmed: 9096394
Adv Healthc Mater. 2012 Sep;1(5):537-47
pubmed: 23184788
Angew Chem Int Ed Engl. 2019 Jun 24;58(26):8804-8808
pubmed: 31033145
Invest New Drugs. 2020 Dec;38(6):1641-1652
pubmed: 32361788
Nat Nanotechnol. 2018 Sep;13(9):862-869
pubmed: 29915272
Cancer Cell. 2017 Nov 13;32(5):561-573.e6
pubmed: 29033244
Nat Nanotechnol. 2016 Apr;11(4):372-7
pubmed: 26878141
Angew Chem Int Ed Engl. 2016 Aug 16;55(34):10003-7
pubmed: 27411830
Colloids Surf B Biointerfaces. 2004 Apr 15;34(4):253-8
pubmed: 15261065
Adv Mater. 2018 Jun;30(23):e1706759
pubmed: 29582476
Theranostics. 2019 Jan 1;9(1):48-64
pubmed: 30662553
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Biol Chem. 2003 Dec 26;278(52):52231-9
pubmed: 14557269
J Drug Target. 2019 Aug;27(7):742-761
pubmed: 30239255
Nano Lett. 2018 Apr 11;18(4):2411-2419
pubmed: 29561622
Cancer Lett. 2020 Jul 28;483:87-97
pubmed: 32268165
J Nanobiotechnology. 2021 Jan 6;19(1):9
pubmed: 33407570
Nano Lett. 2005 Aug;5(8):1615-9
pubmed: 16089498
Angew Chem Int Ed Engl. 2017 Nov 6;56(45):14075-14079
pubmed: 28892588
ACS Nano. 2018 Nov 27;12(11):11386-11398
pubmed: 30372038
Theranostics. 2020 Jul 9;10(18):8179-8196
pubmed: 32724465
ACS Nano. 2016 Mar 22;10(3):3723-37
pubmed: 26882007
Sci Adv. 2020 Jul 15;6(29):eaay9249
pubmed: 32832614
J Clin Invest. 2001 Jun;107(12):1499-500
pubmed: 11413154
Semin Oncol Nurs. 1993 Nov;9(4 Suppl 2):6-10
pubmed: 7904378
Biomaterials. 2016 Jun;92:13-24
pubmed: 27031929
Biomaterials. 2014 Jan;35(2):771-8
pubmed: 24148240
Acta Pharm Sin B. 2019 Jul;9(4):675-689
pubmed: 31384529
Theranostics. 2016 Apr 28;6(7):1004-11
pubmed: 27217833
Biomaterials. 2019 Feb;192:292-308
pubmed: 30465973
J Natl Cancer Inst Monogr. 1993;(15):69-78
pubmed: 7912532
Br J Pharmacol. 2019 Jun;176(12):2079-2094
pubmed: 30825187
ACS Appl Mater Interfaces. 2019 Feb 6;11(5):4790-4798
pubmed: 30624037
Adv Mater. 2018 Dec;30(51):e1803717
pubmed: 30328157
Cancer Res. 2006 Jan 15;66(2):999-1006
pubmed: 16424035
Cell Death Dis. 2019 Oct 28;10(11):821
pubmed: 31659154
Bioconjug Chem. 2017 Jan 18;28(1):23-32
pubmed: 27798829
Expert Opin Biol Ther. 2012 Apr;12(4):385-9
pubmed: 22332936
J Am Chem Soc. 2015 May 13;137(18):6000-10
pubmed: 25869911
Nanomicro Lett. 2020 Jun 16;12(1):129
pubmed: 34138128
Nanotoxicology. 2020 Aug;14(6):774-787
pubmed: 32401088
Annu Rev Cell Dev Biol. 2013;29:471-99
pubmed: 23875648
Anticancer Res. 1994 May-Jun;14(3A):915-9
pubmed: 8074493
Oncogene. 2006 Aug 7;25(34):4683-96
pubmed: 16892082
Cell. 2014 May 22;157(5):1117-29
pubmed: 24855948
Eur J Pharm Sci. 2010 Oct 9;41(2):369-75
pubmed: 20633647
Oncol Lett. 2018 Apr;15(4):5627-5633
pubmed: 29552200
Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):10980-5
pubmed: 21690347
Annu Rev Immunol. 2014;32:25-50
pubmed: 24215318
Theranostics. 2019 Sep 20;9(23):6809-6823
pubmed: 31660070
Oncogene. 2017 Jun 1;36(22):3137-3148
pubmed: 27941877
Adv Mater. 2018 Nov;30(47):e1802394
pubmed: 30182451
Sci Technol Adv Mater. 2019 Jun 26;20(1):710-724
pubmed: 31275462
ACS Nano. 2019 Dec 24;13(12):13965-13984
pubmed: 31730327
ACS Nano. 2019 Apr 23;13(4):4742-4751
pubmed: 30964974
J Control Release. 2020 May 10;321:564-575
pubmed: 32112854
Theranostics. 2019 May 26;9(12):3580-3594
pubmed: 31281499
Adv Drug Deliv Rev. 2016 Feb 1;97:204-36
pubmed: 26592477
Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14623-8
pubmed: 16199525
J Control Release. 2013 Nov 28;172(1):38-47
pubmed: 23933235
Biomaterials. 2018 May;165:39-47
pubmed: 29501968
Cancer Cell. 2008 Dec 9;14(6):458-70
pubmed: 19061837
Nat Commun. 2018 Jul 30;9(1):2982
pubmed: 30061672
Curr Biol. 2001 Mar 6;11(5):318-29
pubmed: 11267868
Adv Mater. 2019 Aug;31(34):e1803549
pubmed: 30773699
Adv Mater. 2019 Jun;31(23):e1900192
pubmed: 30916367
Nanomedicine. 2020 Aug;28:102212
pubmed: 32334099